# Antibiotic Outcomes of Enterococcal Urinary Tract Infections: A Retrospective Analysis from Saudi Arabia and Oman

**Authors:** Abrar K. Thabit, Juhaina S. Al-Maqbali, Khaled F. Alharthi, Salem M. Baotab, Abdullah M. Bankhar, Rayyan M. Wali, Mohammed O. Alzahrani, Asiya K. Alharthi, Taqwa M. Alhamsaidi, Ibrahim Al Busaidi, Ahmad J. Mahrous, Jimmy Jose

PMC · DOI: 10.3390/pathogens15030250 · Pathogens · 2026-02-26

## TL;DR

This study examines antibiotic outcomes for enterococcal UTIs in Saudi Arabia and Oman, finding that E. faecalis responds better to treatment than E. faecium.

## Contribution

The study provides new insights into treatment outcomes and risk factors for enterococcal UTIs in the Arabian region.

## Key findings

- E. faecalis was associated with higher clinical cure rates and lower mortality compared to E. faecium.
- Ciprofloxacin showed high odds of clinical cure, while cancer chemotherapy and prior infections lowered cure odds.
- Urinary catheter removal was linked to lower recurrence rates.

## Abstract

Background: Enterococcus species are involved in urinary tract infections (UTIs), and they are known to be intrinsically resistant to certain antibiotics. We aimed to investigate the clinical characteristics and treatment outcomes of enterococcal UTIs in three hospitals in Saudi Arabia and Oman. Methods: A retrospective cohort study was conducted on adults with clinically and microbiologically confirmed enterococcal UTI based on urinary symptoms and a urine culture of ≥100,000 CFU/mL, who received an antibiotic active against the pathogen. The primary endpoint was clinical cure. Secondary endpoints included microbiological cure, length of stay (LOS), in-hospital mortality, and recurrence. Results: E. faecalis and E. faecium were isolated from 188 (67.1%) and 92 (32.9%), respectively, of 280 included patients. Ampicillin/amoxicillin (25%) and vancomycin (22.1%) were the most-used antibiotics. Compared with E. faecium, E. faecalis was associated with higher clinical cure rates (75% vs. 57.6%; p = 0.003), lower in-hospital mortality (15.7% vs. 38.5%; p < 0.0001), and shorter LOS (12.5 vs. 25 days; p < 0.0001). No difference in recurrence was observed. Ciprofloxacin was associated with high odds of clinical cure (OR, 4.28; 95% CI, 1.18–15.56). Conversely, the recent cancer chemotherapy and growth of Enterococcus at another site were associated with lower odds of clinical cure. Urinary catheter removal was associated with lower recurrence odds (OR, 0.48; 95% CI, 0.24–0.98). Conclusions: This study highlights the clinical challenges posed by enterococcal UTIs, particularly by E. faecium. Ciprofloxacin remains an effective option, particularly against E. faecalis. Patients with advanced age, critical illness, complicated infections, and liver disease, as well as patients on hemodialysis, require close monitoring to improve outcomes.

## Linked entities

- **Chemicals:** Ampicillin (PubChem CID 6249), Amoxicillin (PubChem CID 33613), Vancomycin (PubChem CID 14969), Ciprofloxacin (PubChem CID 2764)
- **Diseases:** Liver disease (MONDO:0005154), Cancer (MONDO:0004992)
- **Species:** Enterococcus faecalis (taxon 1351), Enterococcus faecium (taxon 1352)

## Full-text entities

- **Diseases:** liver disease (MESH:D008107), cancer (MESH:D009369), Enterococcal Urinary Tract Infections (MESH:D014552), infections (MESH:D007239)
- **Chemicals:** vancomycin (MESH:D014640), Ciprofloxacin (MESH:D002939), Ampicillin (MESH:D000667), amoxicillin (MESH:D000658)
- **Species:** Enterococcus faecalis (species) [taxon 1351], Enterococcus faecium (species) [taxon 1352], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13028684/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC13028684/full.md

---
Source: https://tomesphere.com/paper/PMC13028684